Abstract #3852
Non-invasive assessment of PD-L1 expression status in non-small cell lung cancer using multi-parametric 18F-FDG PET/MRI
Nan Meng1, Fangfang Fu2, Zhun Huang3, Ziqiang Li4, Yu Luo1, Pengyang Feng3, Yaping Wu2, Jianmin Yuan5, Yang Yang6, and Meiyun Wang*1
1Department of Medical Imaging, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital, Zhengzhou, China, 2Department of Medical Imaging, Henan Provincial People’s Hospital, Zhengzhou, China, 3Department of Medical Imaging, Henan University People’s Hospital & Henan Provincial People’s Hospital, Zhengzhou, China, 4Department of Medical Imaging, Xinxiang Medical University Henan Provincial People’s Hospital, Zhengzhou, China, 5Central Research Institute, UIH Group, Shanghai, China, 6Beijing United Imaging Research Institute of Intelligent Imaging, UIH Group, Beijing, China
Synopsis
18F-Fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) allows multimodal quantitative MRI sequences to be scanned in parallel with PET imaging, providing a more multidimensional reflection of lesion information. Our results showed that intravoxel incoherent motion (IVIM), amide proton transfer-weighted imaging (APTWI), and metabolism related parameters can be beneficial for the non-invasive assessment of PD-L1 expression in NSCLC patients, and the combination of SUVmax, D, and MTRasym(3.5ppm) may serve as a prognostic biomarker to guide immunotherapy.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
